力生制药：子公司药品阿普米司特片通过上市许可申请

Core Viewpoint - The announcement indicates that the subsidiary of the company, Central Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for Apremilast tablets in 10mg, 20mg, and 30mg specifications, which has passed the marketing authorization application [1] Group 1 - The drug is classified as a Class 4 chemical drug and is intended for the treatment of moderate to severe plaque psoriasis in adult patients [1] - The approval will enrich the company's product line for psoriasis treatment and expand market sales [1] - The future performance impact is expected to be positive, although drug sales may be influenced by market conditions and other factors, leading to uncertainty [1]